TrialBlood advances2023

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.

Jeremy S Abramson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.